A novel immunotherapeutic treatment for experimental hepatocellular carcinoma (HCC) using the host-defense derived peptide LTX-315

被引：0
|
作者：
Line, Pal Dag [1 ,3 ]
Shi, Jihua [1 ,3 ]
Nestvold, Janne M. [2 ]
Wang, Meng Yu [2 ]
Kvalheim, Gunnar [2 ]
Rekdal, Oystein [4 ,5 ]
机构：
[1] Oslo Univ Hosp, Dept Transplantat, Oslo, Norway
[2] Oslo Univ Hosp, Dept Canc Med, Oslo, Norway
[3] Oslo Univ Hosp, Inst Surg Res, Oslo, Norway
[4] Univ Tromso, Dept Med Biol, Tromso, Norway
[5] Lytix Biopharma, Oslo, Norway
来源：
HEPATOLOGY | 2013年 / 58卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
250
引用
收藏
页码：332A / 332A
页数：1
相关论文
共 6 条
  • [1] LTX-315 - a promising novel antitumor peptide and immunotherapeutic agent
    Zweytick, Dagmar
    CELL STRESS, 2019, 3 (11) : 328 - 329
  • [2] LTX-315 (Oncopore™) A short synthetic anticancer peptide and novel immunotherapeutic agent
    Camilio, Ketil Andre
    Rekdal, Oystein
    Sveinbjornsson, Baldur
    ONCOIMMUNOLOGY, 2014, 3 (06)
  • [3] Treatment of Experimental Hepatocellular Carcinoma (HCC) Using a Novel Engineered Host Defence Peptide
    Line, Pal-Dag
    Shi, Ji-Hua
    Kvalheim, Gunnar
    Sveinbjornsson, Baldur
    Rekdal, Oystein
    LIVER TRANSPLANTATION, 2014, 20 : S134 - S134
  • [4] TREATMENTS OF EXPERIMENTAL HEPATOCELLULAR CARCINOMA USING A NOVEL ENGINEERED HOST DEFENCE PEPTIDE
    Shi, J. H.
    Hammarstrom, C. L.
    Rekdal, O.
    Line, P. D.
    JOURNAL OF HEPATOLOGY, 2016, 64 : S566 - S566
  • [5] Oncolytic peptide LTX-315 plus an anti-CTLA-4 antibody induces a synergistic anti-cancer immune response in residual tumors after radiofrequency ablation of hepatocellular carcinoma
    Bo Sun
    Jiayun Liu
    Xiaocui Liu
    Jing Li
    Guilin Zhang
    Tao Sun
    Chuansheng Zheng
    Xuefeng Kan
    Cell Death & Disease, 16 (1)
  • [6] Experimental study of iodine-131 labeling of a novel tumor-targeting peptide, TFMP-Y4, in the treatment of hepatocellular carcinoma with internal irradiation
    Du, Juan
    Ren, Weiwei
    Liu, Wenjie
    Zhou, Yixuan
    Li, Yushan
    Lai, Qingyi
    Liu, Xiongying
    Chen, Tongsheng
    Liu, Wenjuan
    Chen, Zhuanming
    Zhang, Jinhe
    Zhang, Peipei
    Yuan, Jianwei
    BMC CANCER, 2025, 25 (01)
1